| 褚秀丽,张 琳,丁 军,曹合利,徐 晨.基于SDF-1/CXCR4信号通路探讨醒脑静注射液联合尼莫地平促进
高血压脑出血患者神经功能恢复的作用研究[J].,2024,(22):4224-4226 |
| 基于SDF-1/CXCR4信号通路探讨醒脑静注射液联合尼莫地平促进
高血压脑出血患者神经功能恢复的作用研究 |
| Exploring the Effect of Xingnaojing Injection Combined with Nimodipineon the Recovery of Neurological Function in Patients with Hypertensive Intracerebral Hemorrhage Based on SDF-1/CXCR4 Signaling Pathway |
| 投稿时间：2024-07-02 修订日期：2024-07-28 |
| DOI：10.13241/j.cnki.pmb.2024.22.005 |
| 中文关键词: 高血压脑出血 SDF-1/CXCR4信号通路 醒脑静注射液 尼莫地平 神经功能 |
| 英文关键词: |
| 基金项目:上海市科委科技创新行动计划项目（19411968100） |
|
| 摘要点击次数: 97 |
| 全文下载次数: 62 |
| 中文摘要: |
| 摘要 目的：基于基质细胞衍生因子-1（SDF-1）/CXC趋化因子受体4（CXCR4）信号通路，探讨醒脑静注射液联合尼莫地平促进高血压脑出血（HICH）患者神经功能恢复的作用。方法：采用随机数字表法将132例HICH患者分为对照组（接受尼莫地平治疗，66例）和研究组（对照组基础上接受醒脑静注射液治疗，66例）。对比两组血清神经细胞因子指标、血清SDF-1、CXCR4水平、脑卒中患者生活质量疾病专用量表（SIS）评分、美国国立卫生研究院卒中量表（NIHSS）评分、改良Rankin量表（mRS）评分的变化情况。结果：治疗14 d后，两组血清神经元特异性烯醇化酶（NSE）、髓鞘碱性蛋白（MBP）、神经胶质纤维酸性蛋白（GFAP）、SDF-1、CXCR4水平均下降，且研究组下降更为明显（P＜0.05）。治疗3个月后，两组NIHSS、mRS评分均下降，且研究组改善幅度更大（P＜0.05）；两组SIS各维度评分均升高，且研究组改善幅度更大（PP＜0.05）。结论：醒脑静注射液联合尼莫地平可显著改善HICH患者预后，促进神经功能恢复，其作用机制可能与调控SDF-1/CXCR4信号通路有关。 |
| 英文摘要: |
| ABSTRACT Objective: Based on the stromal cell-derived factor-1 (SDF-1)/CXC chemokine receptor 4 (CXCR4) signaling pathway, to investigate the effect of xingnaojing injection combined with nimodipine on the recovery of neurological function in patients with hypertensive intracerebral hemorrhage (HICH). Methods: Using a random number table method, 132 patients with HICH were divided into control group (treated with nimodipine, 66 cases) and research group (treated with xingnaojing injection on the basis of control group, 66 cases). The changes of serum nerve cell factor indexes, serum SDF-1, CXCR4 levels, quality of life disease scale (SIS) score, national institutes of health stroke scale (NIHSS) score and modified Rankin scale (mRS) score were compared in two groups. Results: After 14 days of treatment, the levels of serum neuron-specific enolase (NSE), myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), SDF-1 and CXCR4 in two groups decreased, and the decrease was more significant in the research group(P<0.05). After 3 months of treatment, the NIHSS and mRS scores in two groups decreased, and research group improved more significantly(P<0.05). The scores of SIS in each dimension in two groups increased, and research group improved more significantly(P<0.05). Conclusion: Xingnaojing injection combined with nimodipine can significantly improve the prognosis of HICH patients, and promote the recovery of neurological function, the mechanism may be related to the regulation of SDF-1/CXCR4 signaling pathway. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
